Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Editas Medicine

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Editas Medicine reports positive clinical data and strategic advancements

Editas Medicine's Q4 2022 earnings call highlighted positive clinical data, strong financial positioning, and strategic advancements in genome editing medicines.
While facing challenges in hiring key personnel, regulatory negotiations, and strategic realignment, the company is well-positioned for therapeutic advancements and market growth.
Opportunities lie in replicating clinical success, strategic partnerships, and advancements in pipeline development, supported by strong collaborations and financial prospects.
Overall, Editas Medicine's performance, strengths, challenges, and opportunities reflect a company poised for continued growth and innovation in the genome editing space.

Editas Medicine excels in Q1 with promising trials and regulatory progress

Editas Medicine's Q1 performance was strong, supported by promising clinical trial data and regulatory advancements.
The company's focus on gene editing for hemoglobinopathies and strong IP position are key strengths.
Challenges include differentiation from competitors and legal uncertainties, while opportunities lie in expansion and regulatory progress.
Overall, Editas Medicine is well-positioned for growth in the gene editing market.

Editas Medicine reports positive data, raises funds, and faces challenges

Editas Medicine shows strong performance with positive clinical data and financial raise
Facing challenges in pipeline adjustment and FDA discussions for facility planning
Opportunities lie in expanding trials, partnerships, and enhancing R&D focus

Editas Medicine advances EDIT-301 program, poised for gene therapy leadership

Editas Medicine is making significant progress with EDIT-301, showcasing confidence in their gene editing capabilities and operational readiness.
While facing challenges in safety monitoring and differentiation, the company's strategic hires, strong IP portfolio, and focus on regulatory pathways provide a solid foundation for growth.
With a clear roadmap for clinical data presentation, manufacturing scaling, and regulatory submissions, Editas is well-positioned to capitalize on opportunities in gene editing therapies.

Editas Medicine exceeds enrollment goals and showcases promising clinical data

Editas Medicine's Q4 2023 Earnings Call showcased strong performance in enrollment, clinical data, and financials. The company's strengths lie in its research capabilities, cash position, and progress in key trials. Challenges include addressing analyst queries and optimizing manufacturing processes.

Editas Medicine reports robust Q1 performance and advances in gene editing

Editas Medicine's Q1 2024 performance reflects solid revenue and strong financial reserves, driven by R&D investments in the Renace program.
The company's strengths lie in its financial stability, advancing in vivo capabilities, and fostering strong collaborations for future growth.
Challenges include legal uncertainties, operational optimizations, and strategic complexities in therapeutic development.
Opportunities abound in driving Renace, regulatory progress for Reni-cel, and leveraging innovative in vivo approaches for unique indications.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Editas Medicine, Inc. (NASDAQ:EDIT ) Stifel 2023 Healthcare Conference November 14, 2023 1:50 PM ET Company Participants Erick Lucera - EVP, CFO Cristi Barnett - VP, Corporate Communications and IR Conference Call Participants Dae Gon Ha - Stifel Dae Gon Ha Okay, let's go ahead and get started with the next session. Thanks everyone for joining us.

Editas Medicine, Inc. (EDIT) Presents at Stifel 2023 Healthcare Conference (Transcript)

CRISPR Therapeutics

Intellia Therapeutics

The fields of gene editing and gene therapy have been growing since the first draft of the human genome map was finished in 2003. In 2022, gaps in that map were completed.

3 Biotech Stocks That Are Betting on the Future of Gene Editing

Editas' (EDIT) third-quarter 2023 results reflect a year-over-year increase in revenues. The stock of the company rises 18%.

Editas (EDIT) Q3 Earnings & Revenues Beat, Pipeline in Focus

Editas Medicine, Inc. (EDIT) Q3 2023 Earnings Call Transcript

Editas Medicine (EDIT) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to loss of $0.81 per share a year ago.

Editas Medicine (EDIT) Reports Q3 Loss, Tops Revenue Estimates

Company to provide a clinical update on the EDIT-301 RUBY trial for SCD and EdiTHAL trial for TDT in December at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored webinar

Editas Medicine Announces Third Quarter 2023 Results and Business Updates

Company to host a webinar to discuss EDIT-301 clinical data on Monday, December 11, at 1:00 p.m. ET Dr. Rabi Hanna from Cleveland Clinic Children's to present EDIT-301 clinical data at ASH on Monday, December 11 CAMBRIDGE, Mass.

Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of EDIT-301 at the ASH 2023 Annual Meeting and in a Company-sponsored Webinar

Amgen

bluebird bio

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

The Food and Drug Administration will hold an advisory committee meeting for the first CRISPR/Cas9 gene-edited product candidate this week. If approved, CRISPR Therapeutics and Vertex Pharmaceuticals' sickle cell disease therapy could generate blockbuster sales figures.

Gene Therapy Could Be On the Cusp of a Major Breakthrough, but Investors May Have to Remain Patient

CAMBRIDGE, Mass., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a conference call and webcast on Friday, November 3, 2023, at 8:00 a.m. ET to discuss results for the third quarter 2023 and to provide a corporate update.

Editas Medicine Announces Third Quarter 2023 Results Conference Call and Upcoming Investor Events

Global X Genomics & Biotechnology ETF

Gene editing is revolutionizing how the world approaches medicine. In fact, by “simply” removing cells from the body, editing them, and reintroducing them, we could help treat sickle-cell anemia, cancers, blood disorders, blindness, cystic fibrosis, and even muscular dystrophy if all goes according to plan.

3 Gene Editing Stocks to Generate Super-Charged Gains

Beam Therapeutics

Don't buy biotech stocks unless your portfolio is properly diversified already. Beam Therapeutics might eventually have a competitive advantage in manufacturing.

1 Risky Biotech Stock to Consider Buying, and 1 to Avoid

The FDA bestows Regenerative Medicine Advanced Therapy designation to Editas' (EDIT) gene editing therapy, EDIT-301, for the treatment of severe sickle cell disease. Shares rise.

Editas (EDIT) Gets FDA's RMAT Tag for Gene Therapy to Treat SCD

CAMBRIDGE, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to EDIT-301, an investigational, gene editing medicine, for the treatment of severe sickle cell disease (SCD).

Editas Medicine Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EDIT-301 for the Treatment of Severe Sickle Cell Disease

Editas Medicine specializes in gene editing, targeting a range of serious illnesses, with a unique platform that covers over 95% of the human genome. EDIT's collaboration with Bristol-Myers Squibb aims to revolutionize cancer treatments, especially in cancer immunotherapy. EDIT faces competition in the gene therapy race for Sickle Cell Disease from Bluebird Bio and CRISPR Therapeutics, with BLUE and CRSP being more advanced in their clinical trials.

Editas Medicine: A Mispriced Contender In The Gene Editing Arena

Editas uses an untraditional gene-editing technique. The company is in the clinical stage with no approved therapies yet.

Is Editas Stock a Buy Now?

Biotech stocks are highly risky even when they're notching successes. Issuing stock and taking out debt are not equivalent risks for shareholders.

Avoid Big Losses With Biotech Stocks by Paying Attention to These 2 Things

Editas Medicine's reduced R&D costs and strong cash position provide operational comfort but necessitate future capital, especially amid looming competition from exa-cel. EDIT-301 shows early promise in sickle cell disease, pivotal for Editas' valuation as it approaches critical milestones, including RUBY trial results and FDA decision on competitor exa-cel. Investment Recommendation: Buy Editas for its stable finances and early-stage clinical promise in EDIT-301, albeit with cognizance of high-risk factors like competition and potential financing needs.

Editas Medicine: RUBY Gems, Sparkling Catalysts In Sickle Cell Arena

Editas Medicine and CRISPR Therapeutics are racing towards the same market. It looks like Bluebird Bio is going to be the player to beat in that market.

Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics

Stifel upgraded Editas Medicine stock from hold to buy and raised the price target from $9 to $17. The upgrade reflects optimism about Editas' progress in developing a gene-editing therapy targeting sickle cell disease.

Why Editas Medicine Stock Is Soaring Today

Editas Medicine, Inc. (NASDAQ:EDIT ) Cantor Global Healthcare Conference 2023 Call September 26, 2023 1:35 PM ET Company Participants Baisong Mei - Senior Vice President and Chief Medical Officer Erick Lucera - Executive Vice President and Chief Financial Officer Conference Call Participants Rick Bienkowski - Cantor Fitzgerald Rick Bienkowski Good afternoon, everyone. Welcome back to the Cantor Fitzgerald Global Healthcare Conference.

Editas Medicine, Inc. (EDIT) Cantor Global Healthcare Conference 2023 - (Transcript)

CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the grant of an inducement award to the Company's newly appointed Chief Commercial and Strategy Officer, Caren Deardorf. In connection with Ms. Deardorf's appointment, the Editas Medicine Board of Directors approved a stock option grant to Ms. Deardorf as an inducement material to Ms. Deardorf entering into employment with Editas Medicine in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option provides for the purchase of up to 123,350 shares of Editas Medicine common stock at a price of $8.00 per share, the closing price per share of Editas Medicine common stock as reported by Nasdaq on the date of grant, and vests over four years, with 25 percent of the shares vesting on the first anniversary of Ms. Deardorf's employment start date, and the remainder vesting ratably at the end of each subsequent month thereafter, subject to Ms. Deardorf's continued service relationship with Editas Medicine through the applicable vesting dates.

Editas Medicine Reports Inducement Grants to New Chief Commercial and Strategy Officer

CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the appointment of Caren Deardorf as the Company's first Chief Commercial and Strategy Officer. Ms. Deardorf will build and lead Editas Medicine's commercial organization, strategy, and execution to support all launch, commercialization, and lifecycle management activities of the Company's current and future pipeline of products.

Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer

Biogen

BioMarin Pharmaceutical

Novartis

Solid Biosciences

Sarepta Therapeutics

It's not often that you see a company whose main product comes with a price tag of over $2 million, but that's the case with biotechs BioMarin Pharmaceutical NASDAQ: BMRN and Sarepta Therapeutics NASDAQ: SRPT, which are developing gene therapies. ‘

Are Gene Therapy Stocks The Market's Next Big Winners?

Caribou Biosciences

Caribou Biosciences has plenty of money for the next year or so, and great data. Editas Medicine is far behind the competition with its lead programs.

1 Gene Editing Stock to Buy Now, and 1 to Sell

Editas Medicine, Inc. (NASDAQ:EDIT ) Morgan Stanley 21st Annual Global Healthcare Conference Call September 11, 2023 10:00 AM ET Company Participants Gilmore O'Neill - President and Chief Executive Officer Baisong Mei - Senior Vice President and Chief Medical Officer Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn Great. Well, thanks for joining us, everybody.

News for Editas Medicine Stock (EDIT)